NASDAQ:INVA

Innoviva Stock Forecast, Price & News

$13.33
+0.37 (+2.85 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.74
$13.42
50-Day Range
$11.45
$13.96
52-Week Range
$9.21
$15.62
Volume2.46 million shs
Average Volume605,152 shs
Market Capitalization$1.35 billion
P/E Ratio5.87
Dividend YieldN/A
Beta0.61
30 days | 90 days | 365 days | Advanced Chart
Receive INVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.


Innoviva logo

About Innoviva

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.44 out of 5 stars

Medical Sector

676th out of 2,097 stocks

Pharmaceutical Preparations Industry

328th out of 831 stocks

Analyst Opinion: 0.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Innoviva (NASDAQ:INVA) Frequently Asked Questions

Is Innoviva a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" Innoviva stock.
View analyst ratings for Innoviva
or view top-rated stocks.

What stocks does MarketBeat like better than Innoviva?

Wall Street analysts have given Innoviva a "Sell" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Innoviva wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Innoviva's next earnings date?

Innoviva is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Innoviva
.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) issued its earnings results on Wednesday, April, 28th. The biotechnology company reported $0.84 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $0.85. The biotechnology company had revenue of $85.52 million for the quarter. Innoviva had a net margin of 73.65% and a trailing twelve-month return on equity of 47.39%.
View Innoviva's earnings history
.

How has Innoviva's stock been impacted by COVID-19?

Innoviva's stock was trading at $12.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INVA shares have increased by 10.7% and is now trading at $13.33.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for INVA?

1 Wall Street analysts have issued 1-year price objectives for Innoviva's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Innoviva's stock price to reach $10.00 in the next year. This suggests that the stock has a possible downside of 25.0%.
View analysts' price targets for Innoviva
or view top-rated stocks among Wall Street analysts.

Who are Innoviva's key executives?

Innoviva's management team includes the following people:
  • Mr. Pavel Raifeld C.F.A., Chief Exec. Officer (Age 37, Pay $373.97k)
  • Ms. Marianne Zhen CPA, Chief Accounting Officer (Age 52, Pay $433.87k)

Who are some of Innoviva's key competitors?

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.19%), Renaissance Technologies LLC (7.48%), LSV Asset Management (3.51%), Dimensional Fund Advisors LP (2.29%), Putnam Investments LLC (1.75%) and Geode Capital Management LLC (1.13%). Company insiders that own Innoviva stock include George Bickerstaff and Innoviva, Inc.
View institutional ownership trends for Innoviva
.

Which institutional investors are selling Innoviva stock?

INVA stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Bank of New York Mellon Corp, Man Group plc, Arrowstreet Capital Limited Partnership, Atom Investors LP, Goldman Sachs Group Inc., Renaissance Technologies LLC, and Robeco Institutional Asset Management B.V..
View insider buying and selling activity for Innoviva
or view top insider-selling stocks.

Which institutional investors are buying Innoviva stock?

INVA stock was acquired by a variety of institutional investors in the last quarter, including Putnam Investments LLC, Pacer Advisors Inc., State of New Jersey Common Pension Fund D, BlackRock Inc., Geode Capital Management LLC, Denali Advisors LLC, Los Angeles Capital Management LLC, and JPMorgan Chase & Co.. Company insiders that have bought Innoviva stock in the last two years include George Bickerstaff, and Innoviva, Inc.
View insider buying and selling activity for Innoviva
or or view top insider-buying stocks.

How do I buy shares of Innoviva?

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $13.33.

How much money does Innoviva make?

Innoviva has a market capitalization of $1.35 billion and generates $336.79 million in revenue each year. The biotechnology company earns $224.40 million in net income (profit) each year or $2.37 on an earnings per share basis.

How many employees does Innoviva have?

Innoviva employs 5 workers across the globe.

What is Innoviva's official website?

The official website for Innoviva is www.inva.com.

Where are Innoviva's headquarters?

Innoviva is headquartered at 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.